---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-258694"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:34:35.222842+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Benitec reports Q1 FY2025 net loss $5.1M; positive clinical data for BB-301 in OPMD

## Summary
- Net loss $5.1M ($0.48/sh) vs $5.9M ($3.05/sh) prior year; cash $67.8M.
- R&D expenses $3.6M, G&A $2.2M; loss from operations $5.8M.
- Subject 1 had 35% SSQ Total Score improvement at Day 270; Subject 2 normal swallowing profile at Day 180.
- Third subject safely treated with low-dose BB-301 in Oct 2024; fourth expected Dec 2024.
- No serious adverse events observed for treated subjects.

## SEC filing metadata
- accession: 0001193125-24-258694
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524258694/0001193125-24-258694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524258694/d879713d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-258694
- JSON: https://secwatch.observer/filing/0001193125-24-258694.json
- Plain text: https://secwatch.observer/filing/0001193125-24-258694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.